One of Allergan Inc.'s top shareholders has sold nearly all of its holdings in the stock, leaving the Botox maker without the support of a large and long-term investor as it tries to stave off a $53 billion hostile takeover by Valeant Pharmaceuticals International Inc. and activist William Ackman.. Mutual-fund giant Capital Research and Management Co., Allergan's largest holder as of the end of March, sold the shares after meeting with Allergan Chief Executive David Pyott, people familiar with the matter said, although the...
  